SUSMED,Inc.
Notice of Agreement on Termination of Exclusive Sales Agreement for Medcle, an App for Insomnia Disorder
Milestone compensation of 200 million yen confirmed; termination agreement for the exclusive sales contract signed. Sales will continue to be recognized by the company on a standalone basis after termination, with minimal impact. Future consideration of other partnerships.
Key Figures
- Milestone compensation: 200,000,000 yen (confirmed)
- Business revenue to be recorded in Q1 FY2027
- Overall company impact from contract termination is minor
AI要約
Termination of contract and confirmation of milestone compensation
Announces the confirmation of milestone compensation of 200 million yen under the exclusive sales agreement with Shionogi & Co. It is expected to be recorded as business revenue for the first quarter of the fiscal year ending June 2027. In addition, a termination agreement for this contract has been signed.
Future business development and impact
The impact of contract termination on the 2027 fiscal year’s performance is assessed as minor. Going forward, the company will push for standalone sales activities and continue exploring other partnerships. Receipt of milestone payments under the insured listing will continue, but undistributed portions will not be collected.
Sumsumed Corporation
Company overview · Stock price · Financial data · All IR
